Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934865 | 1.00 | SIGMAR1 (0.54) | SIGMAR1HTR2AHRH1ALDH1A1 | |
| SCHEMBL25008394 | 0.92 | SIGMAR1 (0.63) | SIGMAR1HTR2AHRH1ALDH1A1 | |
| SCHEMBL14934945 | 0.89 | HTR2A (0.49) | SIGMAR1HTR2AHRH1ALDH1A1 | |
| SCHEMBL4686477 | 0.89 | HTR2A (0.49) | SIGMAR1HTR2AHRH1ALDH1A1 | |
| SCHEMBL4073277 | 0.87 | SIGMAR1 (0.64) | SIGMAR1HTR2AHRH1 | |
| SCHEMBL11935197 | 0.84 | CXCR4 (0.46) | ALDH1A1 | |
| SCHEMBL11935159 | 0.81 | SCN8A (0.42) | HTR2AHRH1 | |
| SCHEMBL11935162 | 0.80 | MAOA (0.41) | SIGMAR1HTR2AHRH1 | |
| SCHEMBL1967142 | 0.80 | HTR2A (0.56) | SIGMAR1HTR2AHRH1 | |
| SCHEMBL8084177 | 0.80 | SIGMAR1 (0.58) | SIGMAR1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | SIGMAR1 57/4885HTR2A 120/4885HRH1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.